CDT Equity Slides 8.8% as Conduit Pharma Stock Drops 96% Year‑to‑Date
Explore Cdt Equity’s sharp 8.8% drop, its $162k market cap, and how Conduit Pharma’s disease‑agnostic strategy fuels its Nasdaq listing.
2 minutes to read
CDT EQUITY INC
Conduit Pharmaceuticals (CDT) Tumbles 95%: What the Market Losses Mean for Investors
Conduit Pharmaceuticals (CDT) slumps 95% in a year, yet its repurposing strategy and partnership plans hint at potential upside—watch upcoming clinical updates.
3 minutes to read
CDT Equity’s 14.5% Plunge: Why Conduit Pharma Faces a Liquidity and Valuation Crisis
CDT equity plunges 14.5% as Conduit Pharma faces liquidity and valuation gaps—learn why the drug‑agnostic stock is under pressure and what could turn its fortunes.
3 minutes to read